The effect of doxofylline in asthma and COPD

Link to article at PubMed

Respir Med. 2020 Apr;164:105904. doi: 10.1016/j.rmed.2020.105904. Epub 2020 Feb 19.


Theophylline is still one of the most widely prescribed drugs for the treatment of asthma and COPD in developing countries because the majority of asthma and COPD medicines are largely unavailable and also because it is a cheap option. In any case, its anti-inflammatory effects and capacity to reverse corticosteroid resistance deserve consideration, but it can induce numerous side effects and drug-drug interactions and frequently requires measurement of drug levels in plasma. In order to overcome the problems posed by theophylline, other xanthines have been developed. Doxofylline is a newer generation xanthine with both bronchodilating and anti-inflammatory activities and for this reason it has been called "novofylline". It differs substantially from theophylline at the pharmacological level. Clinical studies have shown substantial differences between doxofylline and theophylline. In particular, efficacy/safety profile of doxofylline is better than that of theophylline.

PMID:32094104 | DOI:10.1016/j.rmed.2020.105904

Leave a Reply

Your email address will not be published. Required fields are marked *